CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Parkinson's disease - Management
How do I manage dementia in people with Parkinson's disease?
- Treat any condition that may be causing or exacerbating cognitive impairment, such as depression or acute infection.
- Consider safely reducing or discontinuing (on specialist advice if necessary) any drugs that may be causing or exacerbating cognitive impairment, including:
- Drugs with an antimuscarinic action, including tricyclic antidepressants, tolterodine, and oxybutynin.
- H2-receptor antagonists such as ranitidine.
- Benzodiazepines.
- Amantadine.
- Dopamine agonists.
- Refer for specialist assessment for:
- Optimization of anti-parkinsonian drug regimen, and/or
- Use of a cholinesterase inhibitor. Currently, only rivastigmine is licensed for use in people with Parkinson's disease dementia in the UK.
In depth
© NHS Institute for Innovation and Improvement